160 related articles for article (PubMed ID: 18408341)
21. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
22. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
Agarwal AK
Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243
[TBL] [Abstract][Full Text] [Related]
23. Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.
Lee H; Yang J; Kim H; Kwon JW; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S
J Korean Med Sci; 2010 Nov; 25(11):1676-9. PubMed ID: 21060762
[TBL] [Abstract][Full Text] [Related]
24. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
25. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).
Macdougall IC
Nephrol Dial Transplant; 2001; 16 Suppl 3():14-21. PubMed ID: 11402086
[TBL] [Abstract][Full Text] [Related]
26. Should all patients with chronic kidney disease receive an EPO-type drug?
Berns JS
Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453
[No Abstract] [Full Text] [Related]
27. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
28. Hemoglobin stability and patient compliance with darbepoetin alfa in peritoneal dialysis patients after the implementation of the prospective payment system.
Pirkle JL; Paoli CJ; Russell G; Petersen J; Burkart J
Clin Ther; 2014 Nov; 36(11):1665-74. PubMed ID: 25256386
[TBL] [Abstract][Full Text] [Related]
29. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases.
Chalhoub S; Langston CE; Farrelly J
J Vet Intern Med; 2012; 26(2):363-9. PubMed ID: 22296687
[TBL] [Abstract][Full Text] [Related]
30. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
31. Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents.
Kaufman JS
Am J Kidney Dis; 2013 Feb; 61(2):191-3. PubMed ID: 23318011
[No Abstract] [Full Text] [Related]
32. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
[TBL] [Abstract][Full Text] [Related]
33. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
[TBL] [Abstract][Full Text] [Related]
34. [Erythropoiesis stimulating agents in clinical practice].
Niemczyk L; Dębowska M
Wiad Lek; 2014; 67(3):413-5. PubMed ID: 25782201
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin in kidney disease and type 2 diabetes.
Donnelly S
N Engl J Med; 2011 Jan; 364(4):385; author reply 385-6. PubMed ID: 21268743
[No Abstract] [Full Text] [Related]
37. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
38. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R
Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149
[TBL] [Abstract][Full Text] [Related]
39. Reimbursement for erythropoiesis-stimulating agents poses challenges.
Traynor K
Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
[No Abstract] [Full Text] [Related]
40. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
